The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Roche’s Tecentriq (tezolizumab) in combination with Avastin and chemotherapy as first-line treatment for lung cancer.
Tecentriq is a monoclonal antibody designed to bind with PD-L1 and is recommended for initial treatment for adults with metazoic non-squamous non-small cell lung cancer (NSCLC).
Individuals with EGFR mutant or ALK-positive NSCLS are only recommended Tecentriq, Avastin, paclitaxel and carboplatin after failure of initial targeted therapies.
The decision comes on the back of data from the phase III study IMpower150 involving 1,202 patients that demonstrated individuals with advanced lung cancer lived significantly longer on the combination therapy compared with just Avastin and chemotherapy – the difference being 19.8 months versus 14.9 months.
Sandra Horning, chief medical officer and head of global product development at Roche, said: “We are pleased to receive a positive opinion from the CHMP for this Tecentriq-based combination, which represents a significant step towards bringing a new treatment option to people across Europe with advanced, non-squamous non-small cell lung cancer.”
Lung cancer today is one of the leading causes of death worldwide and NSCLC is the most prevalent accounting for around 85% of cases.